Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Breast Neoplasms"" wg kryterium: Temat


Tytuł:
Native American ancestry and breast cancer risk in Colombian and Mexican women: ruling out potential confounding through ancestry-informative markers.
Autorzy:
Zollner L; Statistical Genetics Research Group, Institute of Medical Biometry, Heidelberg University, Heidelberg, Germany.; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120, Heidelberg, Germany.; Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Torres D; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120, Heidelberg, Germany.; Institute of Human Genetics, Pontificia Universidad Javeriana, Bogotá, Colombia.
Briceno I; Instituto de Genética Humana, Universidad de la Sabana, Bogotá, Colombia.
Gilbert M; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120, Heidelberg, Germany.
Torres-Mejía G; Center for Population Health Research, National Institute of Public Health, Cuernavaca, Morelos, Mexico.
Dennis J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Bolla MK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Wang Q; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Hamann U; Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120, Heidelberg, Germany. .
Lorenzo Bermejo J; Statistical Genetics Research Group, Institute of Medical Biometry, Heidelberg University, Heidelberg, Germany.; Department of Biostatistics for Precision Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
Pokaż więcej
Źródło:
Breast cancer research : BCR [Breast Cancer Res] 2023 Oct 02; Vol. 25 (1), pp. 111. Date of Electronic Publication: 2023 Oct 02.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
MeSH Terms:
American Indian or Alaska Native*/ethnology
American Indian or Alaska Native*/genetics
American Indian or Alaska Native*/statistics & numerical data
Breast Neoplasms*/epidemiology
Breast Neoplasms*/ethnology
Breast Neoplasms*/genetics
Female ; Humans ; Breast ; Colombia/epidemiology ; Mexico/epidemiology ; Triple Negative Breast Neoplasms/epidemiology ; Triple Negative Breast Neoplasms/ethnology ; Triple Negative Breast Neoplasms/genetics
Czasopismo naukowe
Tytuł:
Trichorhinophalangeal syndrome type 1 (TRPS1) expression in male breast carcinoma.
Autorzy:
Law T; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Piotrowski MJ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX 77030, USA.
Ning J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jiang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ding Q; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: .
Sahin AA; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: .
Pokaż więcej
Źródło:
Human pathology [Hum Pathol] 2023 Aug; Vol. 138, pp. 62-67. Date of Electronic Publication: 2023 Jun 16.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*
Breast Neoplasms, Male*/genetics
Female ; Humans ; Male ; Biomarkers, Tumor ; GATA3 Transcription Factor ; Hair Diseases ; Langer-Giedion Syndrome ; Receptors, Estrogen ; Repressor Proteins ; Triple Negative Breast Neoplasms
SCR Disease Name:
Trichorhinophalangeal Syndrome, Type I
Czasopismo naukowe
Tytuł:
Preoperative considerations and benefits of neoadjuvant chemotherapy: insights from a 12-year review of the Hong Kong Breast Cancer Registry.
Autorzy:
Chan YHY; Department of Surgery, Kwong Wah Hospital, Hong Kong SAR, China.
Kwok CCH; Department of Oncology, Princess Margaret Hospital, Hong Kong SAR, China.
Tse DMS; Breast Cancer Research Centre, Hong Kong Breast Cancer Foundation, Hong Kong SAR, China.
Lee HM; Breast Cancer Research Centre, Hong Kong Breast Cancer Foundation, Hong Kong SAR, China.
Tam PY; Breast Cancer Research Centre, Hong Kong Breast Cancer Foundation, Hong Kong SAR, China.
Cheung PSY; Breast Cancer Research Centre, Hong Kong Breast Cancer Foundation, Hong Kong SAR, China.
Pokaż więcej
Źródło:
Hong Kong medical journal = Xianggang yi xue za zhi [Hong Kong Med J] 2023 Jun; Vol. 29 (3), pp. 198-207. Date of Electronic Publication: 2023 Apr 06.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/therapy
Neoadjuvant Therapy*
Humans ; Female ; Hong Kong ; Receptor, ErbB-2 ; Triple Negative Breast Neoplasms ; Treatment Outcome ; Adult ; Middle Aged ; Aged
Czasopismo naukowe
Tytuł:
The association of race/ethnicity in male breast cancer survival within similar comorbidity cohorts.
Autorzy:
Parise CA; Sutter Center for Health Systems Research, Sacramento, California, USA.; Sutter Institute for Medical Research, Sacramento, California, USA.
Caggiano V; Sutter Institute for Medical Research, Sacramento, California, USA.
Pokaż więcej
Źródło:
Cancer [Cancer] 2023 Mar 01; Vol. 129 (5), pp. 750-763. Date of Electronic Publication: 2023 Jan 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural
MeSH Terms:
Breast Neoplasms, Male*/ethnology
Breast Neoplasms, Male*/mortality
Female ; Humans ; Male ; Breast Neoplasms ; Comorbidity ; Ethnicity ; Hispanic or Latino ; Minority Groups ; California/epidemiology ; Registries
Czasopismo naukowe
Tytuł:
Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
Autorzy:
Clark NM; Department of Surgery, University of Washington, Seattle, USA.
Roberts EA; University of Washington School of Medicine, Seattle, USA.
Fedorenko C; Hutchinson Institute for Cancer Outcomes Research Fred Hutchinson Cancer Center, Seattle, USA.
Sun Q; Hutchinson Institute for Cancer Outcomes Research Fred Hutchinson Cancer Center, Seattle, USA.
Dubard-Gault M; Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, USA.; Fred Hutchinson Cancer Center, Seattle, USA.
Handford C; Fred Hutchinson Cancer Center, Seattle, USA.
Yung R; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, USA.
Cheng HH; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, USA.
Sham JG; Department of Surgery, University of Washington, Seattle, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, USA.
Norquist BM; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Flanagan MR; Department of Surgery, University of Washington, Seattle, USA. .; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, USA. .
Pokaż więcej
Źródło:
Annals of surgical oncology [Ann Surg Oncol] 2023 Mar; Vol. 30 (3), pp. 1312-1326. Date of Electronic Publication: 2022 Nov 05.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/genetics
Genetic Testing*
Ovarian Neoplasms*/genetics
Prostatic Neoplasms*/genetics
Pancreatic Neoplasms*/genetics
Female ; Humans ; Male ; Genetic Counseling ; Pancreatic Hormones ; Retrospective Studies ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/pathology
Czasopismo naukowe
Tytuł:
Machine learning analysis of breast ultrasound to classify triple negative and HER2+ breast cancer subtypes.
Autorzy:
Ferre R; Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Elst J; Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Senthilnathan S; Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Lagree A; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Tabbarah S; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Lu FI; Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Sadeghi-Naini A; Department of Electrical Engineering and Computer Science, York University, Toronto, ON, Canada.
Tran WT; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.; Temerty Centre for AI Research and Education, University of Toronto, ON, Canada.
Curpen B; Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.; Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.
Pokaż więcej
Źródło:
Breast disease [Breast Dis] 2023; Vol. 42 (1), pp. 59-66.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/diagnostic imaging
Breast Neoplasms*/metabolism
Breast Neoplasms*/pathology
Machine Learning*
Ultrasonography*
Female ; Humans ; Pilot Projects ; Receptor, ErbB-2/metabolism ; Retrospective Studies ; Triple Negative Breast Neoplasms/diagnostic imaging ; Middle Aged
Czasopismo naukowe
Tytuł:
Brain Metastases in the Setting of Stable Versus Progressing Extracranial Disease Among Patients With Metastatic Breast Cancer.
Autorzy:
Kojundzic I; Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.
Chehade R; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Gonzalez CAC; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Fritz J; Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.
Moravan V; Applied Statistician, VM Stats, Toronto, Ontario, Canada.
Sahgal A; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Warner E; Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Das S; Division of Neurosurgery, St. Michael's Hospital, Toronto, Ontario, Canada.
Jerzak KJ; Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada. Electronic address: .
Pokaż więcej
Źródło:
Clinical breast cancer [Clin Breast Cancer] 2024 Feb; Vol. 24 (2), pp. 156-161. Date of Electronic Publication: 2023 Nov 25.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/therapy
Breast Neoplasms*/pathology
Brain Neoplasms*/secondary
Triple Negative Breast Neoplasms*
Humans ; Female ; Retrospective Studies ; Brain/pathology ; Disease Progression
Czasopismo naukowe
Tytuł:
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
Autorzy:
Brandão M; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.; Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Martins-Branco D; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.
De Angelis C; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.; Clinical Oncology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Vuylsteke P; CHU UCL Namur, Site Ste Elisabeth, UC Louvain, Namur, Belgium.; Department of Internal Medicine, University of Botswana, Gaborone, Botswana.
Gelber RD; Department of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, Frontier Science Foundation, Boston, United States of America.
Van Damme N; Belgian Cancer Registry, Brussels, Belgium.
van Walle L; Belgian Cancer Registry, Brussels, Belgium.
Ferreira AR; Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.; Católica Medical School, Universidade Católica Portuguesa, Rio de Mouro, Portugal.
Lambertini M; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy.; Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Poggio F; Department of Medical Oncology, U.O. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Verhoeven D; Medical Oncology, AZ Klina, University of Antwerp, Antwerp, Belgium.
Barbeaux A; Medical Oncology, CHR Verviers East Belgium, Verviers, Belgium.
Duhoux FP; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Brussels, Belgium.
Wildiers H; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Leuven, Belgium.
Caballero C; Breast International Group, Brussels, Belgium.
Awada A; Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Piccart-Gebhart M; Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Punie K; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Leuven, Belgium.
de Azambuja E; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium. .; Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium. .
Pokaż więcej
Źródło:
Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Jan; Vol. 203 (2), pp. 351-363. Date of Electronic Publication: 2023 Oct 25.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/epidemiology
Breast Neoplasms*/surgery
Breast Neoplasms*/diagnosis
Triple Negative Breast Neoplasms*/pathology
Humans ; Female ; Prognosis ; Belgium/epidemiology ; Neoplasm Staging ; Retrospective Studies
Czasopismo naukowe
Tytuł:
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Autorzy:
Baez-Navarro X; Department of Pathology, Erasmus University Medical Center, 3015 GD, Rotterdam, The Netherlands. .
van den Ende NS; Department of Pathology, Erasmus University Medical Center, 3015 GD, Rotterdam, The Netherlands.
Nguyen AH; Department of Pathology, Erasmus University Medical Center, 3015 GD, Rotterdam, The Netherlands.; Department of Pathology, HMC, The Hague, The Netherlands.
Sinke R; Department of Pathology, Pathan B.V., Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
Westenend P; Laboratory of Pathology, PAL Dordrecht, Dordrecht, The Netherlands.
van Brakel JB; Department of Pathology, Skåne University Hospital, Malmö, Sweden.
Stobbe C; Department of Pathology, Pathan B.V., Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
Westerga J; Department of Pathology, Pathan B.V., Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
van Deurzen CHM; Department of Pathology, Erasmus University Medical Center, 3015 GD, Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
Breast cancer research : BCR [Breast Cancer Res] 2024 Mar 11; Vol. 26 (1), pp. 41. Date of Electronic Publication: 2024 Mar 11.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/pathology
Breast Neoplasms*/pathology
Humans ; Female ; Lymphocytes, Tumor-Infiltrating/metabolism ; Biomarkers, Tumor/metabolism ; Retrospective Studies ; Neoadjuvant Therapy ; Prognosis ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Tytuł:
Decreased Lung Metastasis in Triple Negative Breast Cancer Following Locally Delivered Supratherapeutic Paclitaxel-Loaded Polyglycerol Carbonate Nanoparticle Therapy.
Autorzy:
Sabatelle RC; Departments of Chemistry and Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.
Chu NQ; Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, United States.; Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Blessing W; Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Kharroubi H; Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Bressler E; Departments of Chemistry and Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.
Tsai L; Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, United States.
Shih A; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Grinstaff MW; Departments of Chemistry and Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.
Colson Y; Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, United States.; Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Pokaż więcej
Źródło:
Biomacromolecules [Biomacromolecules] 2024 Mar 11; Vol. 25 (3), pp. 1800-1809. Date of Electronic Publication: 2024 Feb 21.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/pathology
Lung Neoplasms*/drug therapy
Nanoparticles*
Glycerol*
Polymers*
Humans ; Female ; Paclitaxel ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neoplasm Metastasis
Czasopismo naukowe
Tytuł:
Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro.
Autorzy:
Abrahams B; Department of Basic Medical Sciences, Faculty of Health Sciences, University of the Free State, Bloemfontein 9301, South Africa.
Gerber A; Department of Basic Medical Sciences, Faculty of Health Sciences, University of the Free State, Bloemfontein 9301, South Africa.
Hiss DC; Department of Medical Biosciences, Faculty of Natural Sciences, University of the Western Cape, Bellville 7535, South Africa.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Mar 06; Vol. 25 (5). Date of Electronic Publication: 2024 Mar 06.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/pathology
Breast Neoplasms*/metabolism
Humans ; Female ; MCF-7 Cells ; Cell Line, Tumor ; Apoptosis ; Doxorubicin/pharmacology ; ErbB Receptors/metabolism ; Cell Proliferation
Czasopismo naukowe
Tytuł:
Spatial Distribution and Densities of CD103+ and FoxP3+ Tumor Infiltrating Lymphocytes by Digital Analysis for Outcome Prediction in Breast Cancer.
Autorzy:
Chan R; Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, NT, Hong Kong.
Aphivatanasiri C; Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Poon IK; Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, NT, Hong Kong.
Tsang JY; Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, NT, Hong Kong.
Ni Y; Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, NT, Hong Kong.
Lacambra M; Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, NT, Hong Kong.
Li J; Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, NT, Hong Kong.
Lee C; Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, NT, Hong Kong.
Tse GM; Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, NT, Hong Kong.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2024 Mar 04; Vol. 29 (3), pp. e299-e308.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/pathology
Lymphocytes, Tumor-Infiltrating*
Triple Negative Breast Neoplasms*/pathology
Female ; Humans ; Prognosis
Czasopismo naukowe
Tytuł:
HER2-Low Status Was Associated With Better Breast Cancer-Specific Survival in Early-Stage Triple-Negative Breast Cancer.
Autorzy:
Ma Y; Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Jiao D; Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Zhang J; Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Lv M; Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Chen X; Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Liu Z; Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2024 Mar 04; Vol. 29 (3), pp. e309-e318.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/pathology
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/pathology
Humans ; Female ; Breast/pathology ; Prognosis ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism
Czasopismo naukowe
Tytuł:
Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy.
Autorzy:
Yang G; Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Kim JW; Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Lee IJ; Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Jeong J; Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Ahn SG; Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Bae SJ; Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Kim JH; Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Cho Y; Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. .
Pokaż więcej
Źródło:
Yonsei medical journal [Yonsei Med J] 2024 Mar; Vol. 65 (3), pp. 129-136.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/radiotherapy
Breast Neoplasms*/surgery
Humans ; Female ; Neoadjuvant Therapy ; Feasibility Studies ; Combined Modality Therapy ; Neoplasm Staging ; Neoplasm Recurrence, Local/pathology ; Mastectomy, Segmental ; Radiotherapy Dosage
Czasopismo naukowe
Tytuł:
Challenges to genetic testing for germline mutations associated with breast cancer among African Americans Authors.
Autorzy:
Kamaraju S; Medical College of Wisconsin, Milwaukee, WI, USA; Department of Medicine, Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; Froedtert Hospital, Milwaukee, WI, USA. Electronic address: .
Conroy M; Medical College of Wisconsin, Milwaukee, WI, USA; Froedtert Hospital, Milwaukee, WI, USA.
Harris A; Medical College of Wisconsin, Milwaukee, WI, USA; Froedtert Hospital, Milwaukee, WI, USA.
Georgen M; Medical College of Wisconsin, Milwaukee, WI, USA; Department of Medicine, Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; Froedtert Hospital, Milwaukee, WI, USA.
Min H; Medical College of Wisconsin, Milwaukee, WI, USA; Froedtert Hospital, Milwaukee, WI, USA.
Powell M; Medical College of Wisconsin, Milwaukee, WI, USA; Froedtert Hospital, Milwaukee, WI, USA.
Kurzrock R; Medical College of Wisconsin, Milwaukee, WI, USA; Department of Medicine, Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; Froedtert Hospital, Milwaukee, WI, USA.
Pokaż więcej
Źródło:
Cancer treatment reviews [Cancer Treat Rev] 2024 Mar; Vol. 124, pp. 102695. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Breast Neoplasms*/diagnosis
Breast Neoplasms*/genetics
Breast Neoplasms*/epidemiology
Triple Negative Breast Neoplasms*/genetics
Humans ; Female ; BRCA1 Protein/genetics ; Germ-Line Mutation ; Black or African American/genetics ; BRCA2 Protein/genetics ; Genetic Testing/methods
Czasopismo naukowe
Tytuł:
Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry.
Autorzy:
Iwamoto T; Breast and Thyroid Surgery, Kawasaki Medical School Hospital, Okayama, Japan. .
Kumamaru H; Department of Healthcare Quality Assessment, University of Tokyo, Tokyo, Japan.
Niikura N; Department of Breast Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Sagara Y; Department of Breast Surgical Oncology, Social Medical Corporation Hakuaikai, Sagara Hospital, Kagoshima, Japan.
Miyashita M; Department of Breast and Endocrine Surgical Oncology, Tohoku University School of Medicine, Miyagi, Japan.
Konishi T; Department of Breast and Endocrine Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Sanuki N; Radiation Therapy Department, Yokkaichi Municipal Hospital, Mie, Japan.
Tanakura K; Plastic and Reconstructive Surgery, Mitsui Memorial Hospital, Tokyo, Japan.
Nagahashi M; Department of Surgery, Division of Breast and Endocrine Surgery, School of Medicine, Hyogo Medical University, Hyogo, Japan.
Hayashi N; Department of Surgery, Division of Breast Surgical Oncology, Showa University, Tokyo, Japan.
Yoshida M; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
Watanabe C; School of Nursing and Rehabilitation Sciences, Showa University, Tokyo, Japan.
Kinukawa N; Department of Healthcare Quality Assessment, University of Tokyo, Tokyo, Japan.
Toi M; Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.
Saji S; Department of Medical Oncology, Fukushima Medical University, Fukushima, Japan.
Pokaż więcej
Źródło:
Breast cancer (Tokyo, Japan) [Breast Cancer] 2024 Mar; Vol. 31 (2), pp. 185-194. Date of Electronic Publication: 2024 Feb 06.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/epidemiology
Breast Neoplasms*/pathology
Triple Negative Breast Neoplasms*/drug therapy
Humans ; Middle Aged ; Female ; Japan/epidemiology ; Receptor, ErbB-2 ; Epirubicin ; Cyclophosphamide ; Trastuzumab/therapeutic use ; Taxoids/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant ; Registries
Czasopismo naukowe
Tytuł:
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.
Autorzy:
Yıldırım HÇ; Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey. .
Kutlu Y; Department of Medical Oncology, Istanbul Medipol University Medical Faculty, Istanbul, Turkey.
Mutlu E; Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey.
Aykan MB; Department of Medical Oncology, Gulhane Training and Research Hospital, Ankara, Turkey.
Korkmaz M; Department of Medical Oncology, Tokat State Hospital, Tokat, Turkey.
Yalçın S; Department of Medical Oncology, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkey.
Şakalar T; Department of Medical Oncology, Kahramanmaras Necip Fazıl City Hospital, Kahramanmaras, Turkey.
Celayir ÖM; Department of Medical Oncology, MAA Acıbadem University, Istanbul, Turkey.
Kayıkçıoğlu E; Department of Medical Oncology, Süleyman Demirel University, Isparta, Turkey.
Aslan F; Department of Medical Oncology, Medicalpark Ankara Batıkent Hospital, Ankara, Turkey.
Hafızoğlu E; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.
Altıntaş YE; Department of Medical Oncology, Koc University Medical Faculty, Istanbul, Turkey.
Keskinkılıç M; Department of Medical Oncology, Eylül University Faculty of Medicine, İzmir, Turkey.
Chalabiyev E; Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Çelebi A; Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey.
Dursun B; Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Turkey.
Kapar C; Department of Medical Oncology, Bakırkoy Dr. Sadi Konuk Educatıon and Research Hospital, Istanbul, Turkey.
Özen M; Department of Medical Oncology, Sakarya University Faculty of Medicine, Sakarya, Turkey.
Acar Ö; Department of Medical Oncology, Manisa Celal Bayar University Faculty of Medicine, Manisa, Turkey.
Dülgar Ö; Department of Medical Oncology, Umraniye Training and Research Hospital, Istanbul, Turkey.
Kut E; Department of Medical Oncology, Manisa State Hospital, Manisa, Turkey.
Biter S; Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey.
Kus F; Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Almuradova E; Department of Medical Oncology, Tınaztepe Galen Hospital, Izmir, Turkey.
Erdoğan AP; Department of Medical Oncology, Manisa Celal Bayar University Faculty of Medicine, Manisa, Turkey.
Saray S; Department of Medical Oncology, Balıkesir State Hospital, Balıkesir, Turkey.
Güven DC; Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Şimşek ET; Department of Medical Oncology, Anadolu Medical Center, Kocaeli, Turkey.
Üskent N; Department of Medical Oncology, Anadolu Medical Center, Kocaeli, Turkey.
Kemal Y; Department of Medical Oncology, Samsun Medical Park Hospital, Samsun, Turkey.
Çakar B; Department of Medical Oncology, Ege University Faculty of Medicine, İzmir, Turkey.
Açıkgöz Ö; Department of Medical Oncology, Istanbul Medipol University Medical Faculty, Istanbul, Turkey.
Kılıçkap S; Department of Medical Oncology, İstinye University Liv Hospital, Ankara, Turkey.
Aksoy S; Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Pokaż więcej
Źródło:
International journal of clinical oncology [Int J Clin Oncol] 2024 Mar; Vol. 29 (3), pp. 258-265. Date of Electronic Publication: 2024 Feb 04.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Aminopyridines*
Breast Neoplasms*/pathology
Breast Neoplasms, Male*/drug therapy
Breast Neoplasms, Male*/etiology
Piperazines*
Purines*
Pyridines*
Aged ; Humans ; Male ; Middle Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Receptor, ErbB-2/metabolism ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Estimating the risk and benefit of radiation therapy in (y)pN1 stage breast cancer patients: A Bayesian network model incorporating expert knowledge (KROG 22-13).
Autorzy:
Jang BS; Department of Radiation Oncology, Seoul National University Hospital, Seoul, South Korea; Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, South Korea.
Chun SJ; Department of Radiation Oncology, Seoul National University Hospital, Seoul, South Korea.
Choi HS; Department of Radiation Oncology, Seoul National University Hospital, Seoul, South Korea.
Chang JH; Department of Radiation Oncology, Seoul National University Hospital, Seoul, South Korea; Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, South Korea.
Shin KH; Department of Radiation Oncology, Seoul National University Hospital, Seoul, South Korea; Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, South Korea; Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, South Korea. Electronic address: .
Pokaż więcej
Corporate Authors:
Division for Breast Cancer, Korean Radiation Oncology Group
Źródło:
Computer methods and programs in biomedicine [Comput Methods Programs Biomed] 2024 Mar; Vol. 245, pp. 108049. Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/radiotherapy
Breast Neoplasms*/pathology
Triple Negative Breast Neoplasms*/pathology
Triple Negative Breast Neoplasms*/radiotherapy
Triple Negative Breast Neoplasms*/surgery
Humans ; Female ; Mastectomy/methods ; Bayes Theorem ; Neoplasm Staging ; Radiotherapy, Adjuvant/methods
Czasopismo naukowe
Tytuł:
2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan.
Autorzy:
Sagara Y; Department of Breast and Thyroid Surgical Oncology, Hakuaikai Medical Corporation, Sagara Hospital, 3-28 Matsubara, Kagoshima, 892-0833, Japan. .; Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan. .
Kumamaru H; Department of Healthcare Quality Assessment, University of Tokyo, 7‑3‑1 Hongo, Bunkyo‑Ku, Tokyo, 113‑8655, Japan.
Niikura N; Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan.
Miyashita M; Department of Breast and Endocrine Surgical Oncology, Tohoku University School of Medicine, Seiryo‑Machi, Aoba‑Ku, Sendai, 980‑8574, Japan.
Konishi T; Department of Breast and Endocrine Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Iwamoto T; Breast and Thyroid Surgery, Kawasaki Medical School Hospital, Kurashiki, Japan.
Sanuki N; Radiation Therapy Department, Yokkaichi Municipal Hospital, Yokkaichi, Japan.
Tanakura K; Plastic and Reconstructive Surgery, Mitsui Memorial Hospital, 1 Kanda‑Izumicho, Chiyoda‑Ku, Tokyo, 101‑8643, Japan.
Nagahashi M; Division of Breast and Endocrine Surgery, Department of Surgery, School of Medicine, Hyogo Medical University, 1‑1 Mukogawa, Nishinomiya, Hyogo, Japan.
Hayashi N; Department of Breast Surgical Oncology, St. Luke's International Hospital, 9‑1 Akashicho, Chuo‑Ku, Tokyo, 104‑8560, Japan.
Yoshida M; Department of Diagnostic Pathology, National Cancer Center Hospital, 5‑1‑1 Tsukiji, Chuo‑Ku, Tokyo, 104‑0045, Japan.
Kinukawa N; Department of Healthcare Quality Assessment, University of Tokyo, 7‑3‑1 Hongo, Bunkyo‑Ku, Tokyo, 113‑8655, Japan.
Watanabe C; School of Nursing and Rehabilitation Sciences, Showa University, Tokyo, Japan.
Toi M; Tokyo Metropolitan Komagome Hospital, 3 Chome-18 Honkomagome, Bunkyo City, Tokyo, Japan.
Saji S; Department of Medical Oncology, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Pokaż więcej
Źródło:
Breast cancer (Tokyo, Japan) [Breast Cancer] 2024 Mar; Vol. 31 (2), pp. 179-184. Date of Electronic Publication: 2024 Jan 05.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/pathology
Triple Negative Breast Neoplasms*/pathology
Aged ; Female ; Humans ; Male ; Japan/epidemiology ; Receptor, ErbB-2 ; Breast/pathology ; Registries ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Repeat sentinel lymph node surgery for locally recurrent breast cancer after prior mastectomy.
Autorzy:
Schulze AK; Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Hoskin TL; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Mrdutt MM; Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Mutter RW; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Hieken TJ; Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Pokaż więcej
Źródło:
Journal of surgical oncology [J Surg Oncol] 2024 Mar; Vol. 129 (3), pp. 461-467. Date of Electronic Publication: 2023 Nov 06.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/surgery
Breast Neoplasms*/pathology
Sentinel Lymph Node*/surgery
Sentinel Lymph Node*/pathology
Humans ; Female ; Mastectomy ; Sentinel Lymph Node Biopsy ; Lymphatic Metastasis ; Lymph Node Excision ; Axilla/pathology ; Neoplasm Recurrence, Local/surgery ; Neoplasm Recurrence, Local/pathology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies